The Role of the Transcriptional Coactivator p300 in Prostate Cancer Progression

  • Hannelore V. Heemers
  • Jose D. Debes
  • Donald J. Tindall
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)


Although the factors contributing to the progression of prostate cancer (PC) remain incompletely understood, androgens have long been recognized to play a central role in this process. Upon entering PC cells, androgens bind to a cognate nuclear receptor, the androgen receptor (AR). The activated AR translocates to the nucleus, binds as a dimer to androgen response elements (AREs) in the promoter of target genes, where it recruits the coactivator proteins necessary for the formation of a productive transcriptional complex, an event crucial for PC cell viability. For many decades, the androgen dependency of PCs has been exploited therapeutically by androgen ablation strategies. Although initially successful, these forms of therapy almost inevitably fail eventually, and an androgen depletion independent (ADI) disease emerges, for which currently no cure is available. Studies from our laboratory and others demonstrate that despite low circulating levels of functional androgens, the AR is critical for the proliferation and survival of ADI PC cells. Recent data indicate that alterations in the expression and/or activity of AR coactivator proteins occur during PC progression that can foster ADI activation of the AR. Here, we have investigated the role of the coactivator p300 in AR transcriptional activity and progression of PC.


Androgen Receptor P300 Expression LNCaP Cell Prostate Cancer Cell Line Prostate Cancer Progression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687–97.PubMedCrossRefGoogle Scholar
  2. 2.
    Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488–90.PubMedCrossRefGoogle Scholar
  3. 3.
    Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175–200.PubMedCrossRefGoogle Scholar
  4. 4.
    Heemers HV, Tindall DJ (2005) Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr Cancer Ther Rev 1:175–86.CrossRefGoogle Scholar
  5. 5.
    Kalkhoven E (2004) CBP and p300: HATs for different occasions. Biochem Pharmacol 68:1145–55.PubMedCrossRefGoogle Scholar
  6. 6.
    Fu M, Wang C, Reutens AT, et al. (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853–60.PubMedCrossRefGoogle Scholar
  7. 7.
    Fu M, Rao M, Wang C, et al. (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563–75.PubMedCrossRefGoogle Scholar
  8. 8.
    Debes JD, Sebo TJ, Lohse CM, et al. (2003) p300 in prostate cancer proliferation and progression. Cancer Res 63:7638–40.PubMedGoogle Scholar
  9. 9.
    Culig Z, Steiner H, Bartsch G, et al. (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497–505.PubMedCrossRefGoogle Scholar
  10. 10.
    Debes JD, Schmidt LJ, Huang H, et al. (2002) p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632–6.PubMedGoogle Scholar
  11. 11.
    Debes JD, Sebo TJ, Heemers HV, et al. (2005) p300 modulates nuclear morphology in prostate cancer. Cancer Res 65:708–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Gong J, Zhu J, Goodman OB, Jr, et al. (2006) Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene. 25:2011–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Hannelore V. Heemers
    • 1
  • Jose D. Debes
  • Donald J. Tindall
    • 2
  1. 1.Department of Urology ResearchMayo ClinicRochesterUSA
  2. 2.Department of UrologyMayo ClinicRochesterUSA

Personalised recommendations